Associated tags: Medicine, Science, Social responsibility, Pharmaceutical industry, Patient, Sanofi
Locations: AD, DC, WASHINGTON, HAIR, PARIS, FR, FRANCE
Paris, France – March 22, 2024.
Key Points:
- Paris, France – March 22, 2024.
- Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" page of the company's website:
As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
- This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count.
- Sanofi's first-quarter 2024 results will be published on April 25, 2024.
Eosinophil,
Fever,
Week,
Headache,
OX40L,
Conjunctivitis,
Scleroderma,
Teaching hospital,
Atopic dermatitis,
Upper respiratory tract infection,
Part,
Asthma,
TARC,
Conference,
AAD,
Safety,
Biomarker,
Part Two,
Hidradenitis suppurativa,
IGA,
Patient,
Inflammation,
Chills,
Moa,
Serum,
American Academy,
Pharmaceutical industry The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
Key Points:
- The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
- Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
- TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
- Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.
Retrieved on:
Saturday, February 24, 2024
BTK,
QPM,
BID,
AAAAI,
Week,
Omalizumab,
TID,
News,
Prurigo nodularis,
Asthma,
Swelling,
IgG4-related disease,
Skin,
Oral medicine,
UAS7,
Patient,
CSU,
Disease,
Itch,
LSM,
ITT,
American Academy,
Pharmaceutical industry Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.
Key Points:
- Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.
- Significant reduction from baseline to week 12 in weekly urticaria activity score (UAS7) [LSM -17.95 vs -11.20, respectively; p=0.0116].
- Significant reduction from baseline to week 12 in weekly hives severity score (HSS7) [LSM -8.31 vs -4.89; p
- Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.
Retrieved on:
Friday, February 23, 2024
Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Key Points:
- Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Paris, February 23, 2024.
- Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
- These documents are available on the company’s website: https://www.sanofi.com/en/investors/reports-and-publications/financial-r...
In addition, the Form 20-F is available on the website of the SEC ( www.sec.gov ) and the “Document d’Enregistrement Universel” is available on the website of the AMF ( www.amf-france.org ).
- A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.
Retrieved on:
Friday, February 23, 2024
Eosinophil,
Headache,
Diarrhea,
FDA,
Food,
Back pain,
Chronic obstructive pulmonary disease,
Common,
European,
Safety,
COVID-19,
Patient,
Priority,
Diagnosis,
Smoker,
COPD,
Priority review The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).
Key Points:
- The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).
- The target action date for the FDA decision is June 27, 2024.
- In both trials, Dupixent also rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks.
- Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.
Retrieved on:
Thursday, February 22, 2024
Senior,
Audit,
Compass Group,
Immunology,
Clotilde Delbos,
Emlyon Business School,
Henley Business School,
Nomination,
Duke,
Axa,
Bucknell University,
Interim,
Specialization,
Therapy,
Biology,
Committee,
Childhood arthritis,
RCI Banque,
Pechiney,
Pandion,
GSK plc,
PwC,
Division,
Lonrho,
Gilead Sciences,
Merlin,
Corporate responsibility,
Audit committee,
Business administration,
Duke University,
Immune tolerance,
Science,
Annual,
Management Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Key Points:
- Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Paris, February 22, 2024.
- The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office.
- In 2016, Clotilde Delbos was appointed Group Chief Financial Officer and Chairman of Board of Directors of RCI Banque.
- “The arrivals of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy will strengthen the Board of Directors’ expertise in finance and science, notably in the field of immunology.
Retrieved on:
Friday, February 16, 2024
Ministry,
Histamine,
Sinusitis,
Omalizumab,
Quality of life,
Atopic dermatitis,
Prurigo nodularis,
MHLW,
Asthma,
Cell,
Safety,
Patient,
CSU,
Disease,
Polyp (medicine),
Pharmaceutical industry Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs.
Key Points:
- Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs.
- CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and persistent itch.
- CSU is typically treated with histamine (H1) antihistamines, medicines that target H1 receptors on cells to control symptoms of urticaria.
- In addition to CSU, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and prurigo nodularis.
Retrieved on:
Thursday, February 15, 2024
Week,
Railway Workers' Union (Austria),
Headache,
Consortium,
Multiple sclerosis,
Sanofi,
COVID-19,
AFL,
Patient,
Plasma,
Medical imaging Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.
Key Points:
- Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.
- Frexalimab is Sanofi’s novel second-generation investigational anti-CD40L antibody that has a unique method of action with the potential to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion.
- “These published Phase 2 results for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community.
- Sanofi has initiated Phase 3 clinical trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS.
Knowledge,
National Cancer Institute,
Research,
Caregiver,
Patient,
Prevalence,
Diagnosis,
Diversity,
Employee assistance program,
Thought,
Risk,
Journal,
Learning,
Volunteering,
Cancer,
Culture,
Workplace,
Dietary supplement Sanofi today launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses.
Key Points:
- Sanofi today launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses.
- This program covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses*.
- The last thing you want to be thinking about when you are diagnosed with cancer, or going through treatment, is work.
- The program also addresses the emotional wellbeing of Sanofi employees impacted by cancer and other critical illnesses.
Retrieved on:
Thursday, February 1, 2024
François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
Key Points:
- François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
Paris, February 1, 2024.
- François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024.
- He is a seasoned executive who has lived and worked in Europe, the U.S, Asia, Africa and Latin America.
- My decision to head Apprentis d’Auteuil was also fuelled by my growing passion for the impact Sanofi has around the world.
